FDA Approves New Breast Cancer Treatment That Targets Resistance Before Cancer Progresses

The US FDA approved Etcamah (camizestrant) combined with a CDK4/6 inhibitor to treat hormone receptor-positive, HER2-negative advanced breast cancer by targeting ESR1 mutations detected in ctDNA before visible progression. This is the FDA's first approval using a blood test to guide cancer therapy prior to imaging progression, based on phase III trial results showing significantly improved progression-free survival.

This Wire brief sits within Fusion42's coverage of Biotech, and 8 sources have reported it between 4 Sep 2026 and 7 Sep 2026.